BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iyngkaran P, Liew D, Neil C, Driscoll A, Marwick TH, Hare DL. Moving From Heart Failure Guidelines to Clinical Practice: Gaps Contributing to Readmissions in Patients With Multiple Comorbidities and Older Age. Clin Med Insights Cardiol. 2018;12:1179546818809358. [PMID: 30618487 DOI: 10.1177/1179546818809358] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Medvedeva E, Korostovtseva L, Bochkarev M, Shumeiko A, Berezina A, Simonenko M, Sazonova Y, Kozlenok A, Sviryaev Y. The Prognostic Role of Polysomnography Parameters in Heart Failure Patients with Previous Decompensation. JCM 2022;11:3656. [DOI: 10.3390/jcm11133656] [Reference Citation Analysis]
2 Flynn MJ, Kronebusch BJ, Sikkink LA, Swanson KM, Niccum KJ, Crane SJ, Aoun B, Takahashi PY. Impact of the Registered Nurse Clinical Liaison Role in Ambulatory Care on Transitions of Care: A Retrospective Cohort Study. Prof Case Manag 2022;27:58-66. [PMID: 35099419 DOI: 10.1097/NCM.0000000000000538] [Reference Citation Analysis]
3 Iyngkaran P, Thomas M, Majoni SW. Perspectives On Optimizing Chronic Heart Failure Care Beyond Randomised Controlled Trials - What do we Consolidate and how do we Plan for the Future? Curr Cardiol Rev 2019;15:158-60. [PMID: 31084591 DOI: 10.2174/1573403X1503190506101720] [Reference Citation Analysis]
4 Kowalska K, Walczak J, Femlak J, Młynarska E, Franczyk B, Rysz J. Empagliflozin-A New Chance for Patients with Chronic Heart Failure. Pharmaceuticals (Basel) 2021;15:47. [PMID: 35056104 DOI: 10.3390/ph15010047] [Reference Citation Analysis]
5 Gasoyan H, Aaronson WE. Association Between Use of EHR-Generated Dashboards and Hospital Outcomes in 30-Day Heart Failure Readmissions. J Healthc Manag 2020;65:430-40. [PMID: 33186259 DOI: 10.1097/JHM-D-19-00207] [Reference Citation Analysis]
6 Thomas MC, Iyngkaran P. Forensic interrogation of diabetic endothelitis in cardiovascular diseases and clinical translation in heart failure. World J Cardiol 2020; 12(8): 409-418 [PMID: 32879703 DOI: 10.4330/wjc.v12.i8.409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Iyngkaran P, Jelinek M. Health care in a globalised world: is there more than one type of patient? Med J Aust 2019;210:211-2. [PMID: 30773648 DOI: 10.5694/mja2.50035] [Reference Citation Analysis]
8 Regmi MR, Tandan N, Parajuli P, Bhattarai M, Maini R, Kulkarni A, Robinson R. Social Vulnerability Indices as a Risk Factor for Heart Failure Readmissions. Clin Med Res 2021;19:116-22. [PMID: 34531268 DOI: 10.3121/cmr.2021.1603] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Li X, Xu G, Wei S, Zhang B, Yao H, Chen Y, Liu W, Wang B, Zhao J, Gao Y. Lingguizhugan decoction attenuates doxorubicin-induced heart failure in rats by improving TT-SR microstructural remodeling. BMC Complement Altern Med 2019;19:360. [PMID: 31829159 DOI: 10.1186/s12906-019-2771-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]